ALS Phase 2B Study CK-2017357 Report for Patients Like You

Filter by:

All
Start typing to see suggestions

patients

Home > Community Treatment Reports and Side Effects > ALS Phase 2B Study CK-2017357 Treatment Report

You appear to have JavaScript disabled in your browser. PatientsLikeMe relies on JavaScript and Cookies to deliver the best possible experience to you. How do I enable JavaScript?

What is ALS Phase 2B Study CK-2017357?

NCT01378676 is a Phase 2B Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS). Other study ID number is CY 4024.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose	# of patients	# of patients with evaluations Efficacy	Major	Moderate	Slight	None	Can’t tell
Participate in clinical trial	2	2
ALS (Amyotrophic Lateral Sclerosis)	2	2

See all 2 patients currently using ALS Phase 2B Study CK-2017357

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe	0
Moderate	0
Mild	2
None	1

Commonly reported side effects, conditions, and hospitalizations associated with ALS Phase 2B Study CK-2017357

Lightheadedness	1	1
Sleepiness	1	1
Hospitalization	1	1

Reported Schedules

	3 other daily	100,000 mg daily
	1	1

Reported Stop Reasons

Why Patients Stopped Using ALS Phase 2B Study CK-2017357 (multiple reasons could be selected)
Reason	# Patients	Percentage of patients
Other	1

See all 1 patient who’ve stopped using ALS Phase 2B Study CK-2017357

Reported Duration See details about how long patients take this treatment ▼ Reported Duration Hide details ▲

Currently Using ALS Phase 2B Study CK-2017357

A bar graph

0-1 month	1-3 months	3-6 months	6 months-1year	1-2 years	2 years or more
0	0	2	0	0	0

Stopped Using ALS Phase 2B Study CK-2017357

A bar graph

0-1 month	1-3 months	3-6 months	6 months-1year	1-2 years	2 years or more
1	0	0	0	0	0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of ALS Phase 2B Study CK-2017357

Always	3	100%
Usually	0	0%
Sometimes	0	0%
Never	0	0%

Burden

Difficulty being on treatment

Burden of ALS Phase 2B Study CK-2017357

Very	0	0%
Somewhat	0	0%
A little	0	0%
Not at all	3	100%

Cost

Paid out of pocket

Cost of ALS Phase 2B Study CK-2017357

$200+	0	0%
$100-199	0	0%
$50-99	0	0%
$25-49	0	0%
< $25	2	100%

Report created on May 28, 2012.

ALS Phase 2B Study CK-2017357 Treatment Report